YURAK-QON TOMIR KASALLIKLARIDA ERTA SKRININGNING AHAMIYATI
Ключевые слова:
yurak-qon tomir kasalliklari, erta skrining, profilaktika, xavf omillari, arterial gipertenziyaАннотация
Yurak-qon tomir kasalliklari global miqyosda o‘lim va nogironlikning yetakchi sabablaridan biri bo‘lib qolmoqda. Ushbu maqolada yurak-qon tomir kasalliklarining oldini olishda va erta bosqichda aniqlashda skrining tadbirlarining ilmiy va amaliy ahamiyati tahlil qilinadi. Zamonaviy epidemiologik tadqiqotlar, klinik kuzatuvlar hamda xalqaro tavsiyalar asosida arterial gipertenziya, dislipidemiya, qandli diabet va boshqa asosiy xavf omillarini erta aniqlash imkoniyatlari ko‘rib chiqilgan. Erta skriningning aholi salomatligini yaxshilash, yurak xuruji va insult chastotasini kamaytirish hamda sog‘liqni saqlash tizimi xarajatlarini optimallashtirishdagi roli asoslab berilgan. Tadqiqot natijalari profilaktik tibbiyot va ommaviy skrining dasturlarini rivojlantirish zarurligini ko‘rsatadi.
Библиографические ссылки
1. World Health Organization. Cardiovascular diseases (CVDs): Key facts. Geneva: WHO; 2023.
2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982–3021.
3. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries. Lancet. 2020;395(10226):795–808.
4. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596–e646.
5. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
6. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959.
7. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non–laboratory-based method for assessment of cardiovascular disease risk. Lancet. 2008;371(9616):923–931.
8. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
9. Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med. 2013;369(10):954–964.
10. Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349–2358.
11. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for cardiovascular disease risk with electrocardiography. JAMA. 2018;319(22):2308–2314.
12. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381.
13. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation. 2010;121(4):586–613.
14. Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet. 2011;378(9793):752–753.
15. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities. JAMA. 2013;310(9):959–968.
16. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control. Lancet. 2021;398(10304):957–980.
17. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082–e1143
18. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACC secondary prevention and risk reduction therapy update. Circulation. 2011;124(22):2458–2473.
19. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32–38.
20. Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of prevention strategies. Eur Heart J. 2016;37(24):1964–1971.
